Health Secretary Robert F. Kennedy Jr. has directed the Food and Drug Administration to review the nutrients and other ...

Research news last week included Rocket Pharmaceuticals suffering a setback with its Phase II trial of RP-A501, which ...

The Space Launch System rocket's RS-25 engine was fired up for the “final round of certification testing ahead of production ...

China is developing reusable rockets to launch in 2025 and 2026. See the 'net' technology they will use to catch the booster ...

The Mayfield Village Parks & Recreation Department will present the annual vintage car Cruise Night June 14. Also upcoming ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

Paradromics, which directly competes with Elon Musk's Austin-based Neuralink, is looking to build a brain-computer interface ...

Intellia's news comes at a challenging time for gene therapies, as multiple serious adverse events and fatalities have been ...

At Technical.ly’s Builders Conference, lawyers and entrepreneurs each offered blunt advice on how to avoid common early-stage legal errors, from overlooked IP to handshake deals gone wrong.

Northrop Grumman remains a solid, essential defense contractor, but its stock is overvalued with slow growth. Click here to ...

Meanwhile, Merus, a Netherlands-based cancer cure developer, saw its shares jump after unveiling interim phase 2 data for its experimental antibody petosemtamab in combination with pembrolizumab for ...

Regencell's stock soared 17,000% fueled by speculation, despite no revenue or clinical progress. Read why I think the RGC ...